NF-κB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFκB regulatory site in autocrine human multiple myeloma cells

Cancer Biology and Therapy

Volumn 3, Issue 10, 2004, Pages 1007-1017

  Xiao, Weihua ^a   Hodge, David R ^b   Wang, Lihua ^a   Yang, Xiaoyi ^a   Zhang, Xiaohu ^a   Farrar, William L ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autocrine; c Jun; IL 6; IL 6 promoter; Multiple myeloma; NF B

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; CCAAT ENHANCER BINDING PROTEIN BETA;

ARTICLE; AUTOCRINE EFFECT; CELL STRAIN; CONTROLLED STUDY; GENE REPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; STEREOCHEMISTRY; TRANSCRIPTION REGULATION; CELL CULTURE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; REGULATORY SEQUENCE;

CCAAT-ENHANCER-BINDING PROTEIN-BETA; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; REGULATORY SEQUENCES, NUCLEIC ACID; SEQUENCE DELETION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 21244489945     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.10.1141     Document Type: Article

References (40)

1. Keller ET, Wanagat J, Ershler WB. Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1996; 1:d340-57.
2. Frassanito MA, Silvestris F, Silvestris N, Cafforio P, Camarda G, Iodice G, et al. Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clin Exp Immunol 1998; 114:179-88.
3. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis. Blood 2001; 97:483-9.
4. Hirata T, Shimazaki C, Sumikuma T, Ashihara E, Goto H, Inaba T, et al. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res 2003; 27:343-9.
5. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003; 9:4653-65.
6. Szczepek AJ, Belch AR, Pilarski LM. Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: Potential for autocrine and paracrine networks. Exp Hematol 2001; 29:1076-81.
7. Frassanito MA, Cusmai A, Iodice G, Dammacco F Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis. Blood 2001; 97:483-9.
8. Snyers L, Fontaine V, Content J. Modulation of interleukin-6 receptors in human cells. Ann NY Acad Sci 1989; 557:388-93.
9. Lauta VM. A review of the cytokine network in multiple myeloma: Diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97:2440-52.
10. Beetz A, Peter RU, Oppel T, Kaffenberger W, Rupec RA, Meyer M, et al. NF-kappaB and AP-1 are responsible for inducibility of the IL-6 promoter by ionizing radiation in HeLa cells. Int J Radiat Biol 2000; 76:1443-53.
11. Webb SJ, McPherson JR, Pahan K, Koka S. Regulation of TNF-α-induced IL-6 production in MG-63 human osteoblast-like cells. J Dent Res 2002; 81:17-22.
12. Hershko DD, Robb BW, Luo G, Hasselgren PO. Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco2 cells. Am J Physiol Regul Integr Comp Physiol 2002; 283:R1140-R1148.
13. Xiao W, Hodge DR, Wang LH, Yang XY, Zhang X, Farrar WL. Cooperative functions between nuclear factors NFκB and CCAT/Enhancer-binding protein-β(C/EBP-β regulate the IL-6 promoter in autocrine human prostate cancer cells. The Prostate 2004; In press.
14. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63:2206-15.
15. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-47.
16. Xiao W, Wang L, Yang X, Chen T, Hodge D, Johnson PF, et al. CCAAT/enhancer-binding protein β mediates interferon-gamma-induced p48 (ISGF3-γ) gene transcription in human monocytic cells. J Biol Chem 2001; 276:23275-81.
17. Latimer M, Ernst MK, Dunn LL, Drutskaya M, Rice NR. The N-terminal domain of IkappaB α masks the nuclear localization signal(s) of p50 and c-Rel homodimers. Mol Cell Biol 1998; 18:2640-9.
18. Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. Cell Growth Differ 1996; 7:1013-21.
19. Hershko DD, Robb BW, Luo G, Hasselgren PO. Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco2 cells. Am J Physiol Regul Integr Comp Physiol 2002; 283:R1140-R1148.
20. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63:2206-15.
21. Hershko DD, Robb BW, Luo G, Hasselgren PO. Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco2 cells. Am J Physiol Regul Integr Comp Physiol 2002; 283:R1140-8.
22. Webb SJ, McPherson JR, Pahan K, Koka S. Regulation of TNF-α-induced IL-6 production in MG-63 human osteob last-like cells. J Dent Res 2002; 81:17-22.
23. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor KB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63:2206-15.
24. Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. Cell Growth Differ 1996; 7:1013-21.
25. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002; 9:625-36.
26. Deng WG, Zhu Y, Wu KK. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-α-induced cyclooxygenase-2 promoter activation. J Biol Chem 2003; 278:4770-7.
27. Matt T. Transcriptional control of the inflammatory response: A role for the CREB-binding protein (CBP). Acta Med Austriaca 2002; 29:77-9.
28. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 114:2363-73.
29. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10.
30. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein β (C/EBP β) and Rel p50. J Immunol 2001; 106:2378-84.
31. Darieva Z, Lasunskaia EB, Campos MN, Kipnis TL, Da Silva WD. Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-KB-dependent gene transcription in BCG-stimulated macrophages through promotion of p65/p300 binding. J Leukoc Biol 2004; 75:689-97.
32. Duran A, Diaz-Meco MT, Moscat J. Essential role of ReLA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J 2003; 22:3910-8.
33. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C et al. Post-activation turn-off of NF-κ B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003; 278:2758-66.
34. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-κ B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002; 9:625-36.
35. Deng WG, Zhu Y, Wu KK. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-α-induced cyclooxygenase-2 promoter activation. J Biol Chem 2003; 278:4770-7.
36. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-κ B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002; 9:625-36.
37. Goldman PS, Tran VK, Goodman RH. The multifunctional role of the coactivator CBP in transcriptional regulation. Recent Prog Horm Res 1997; 52:103-19.
38. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-κ B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002; 9:625-36.
39. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 114:2363-73.
40. Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 2003; 87:407-16.